SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 798.68 |
| Enterprise Value ($M) | 730.76 |
| Book Value ($M) | 426.45 |
| Book Value / Share | 6.24 |
| Price / Book | 1.87 |
| NCAV ($M) | 325.89 |
| NCAV / Share | 4.77 |
| Price / NCAV | 2.45 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.48 |
| Return on Assets (ROA) | -0.43 |
| Return on Equity (ROE) | -0.52 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.11 |
| Current Ratio | 10.11 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 442.63 |
| Assets | 498.20 |
| Liabilities | 116.74 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -232.85 |
| Net Income | -215.79 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -185.47 |
| Cash from Investing | 97.20 |
| Cash from Financing | 16.28 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Forbion Capital Fund III Cooperatief U.A. | 7.50 | -1.47 | |
| 13G/A | Omega Fund IV, L.P. | 4.00 | -16.62 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 14.50 | 50.85 | |
| 13G/A | Baker Bros. Advisors Lp | 16.20 | 15.71 | |
| 13G/A | Vanguard Group Inc | 5.07 | 0.00 | |
| 13G/A | Morgan Stanley | 2.30 | -64.85 | |
| 13G/A | State Street Corp | 1.73 | -82.15 | |
| 13G/A | Redmile Group, LLC | 7.40 | -19.78 | |
| 13G/A | BlackRock Inc. | 7.70 | 50.75 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 102,336 | 580,023 | 17.64 | |
| 41,265 | 299,754 | 13.77 | |
| 57,585 | 319,784 | 18.01 | |
| 33,030 | 304,475 | 10.85 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RARE – Ultragenyx Pharmaceutical Inc. | RDUS – Radius Recycling, Inc. |
| REGN – Regeneron Pharmaceuticals, Inc. | RGEN – Repligen Corporation |
| RGNX – REGENXBIO Inc. |
Financial data and stock pages provided by
Fintel.io